Bristol-Myers Squibb Co (BMY) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Bristol-Myers Squibb Co (BMS) is a specialty biopharmaceutical company that carries out the discovery, development, licensing, manufacturing, marketing, distribution and sale of medicines to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and virology (including hepatitis B, hepatitis C and HIV infection) therapeutic projects. The company offers its products across the world to retail pharmacies, wholesalers, hospitals, medical professionals and government entities. BMS provides its products in the US, Europe, Japan and other countries. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US.

Bristol-Myers Squibb Co (BMY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

It derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.



List of Tables 8
List of Figures 11
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 17
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deal Details 29
Asset Purchase 29
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 29
Venture Financing 31
Enterome Bioscience Raises USD38.5 Million in Series D Financing 31
TARIS Biomedical Raises USD25 Million in Series B Financing 33
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 35
Cardior Pharma Raises USD16.3 Million in Series A Financing 37
IFM Therapeutics Raises USD27 Million in Series A Financing Round 39
Blade Therapeutics Raises USD27 Million in Series B Financing 40
IFM Therapeutics Raises Funds in Seed Financing Round 42
Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 43
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 44
iPierian Raises USD1 Million in Venture Financing 45
Padlock Therapeutics Raises Funds through Series A Financing 46
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 47
iPierian Raises US$30 Million In Series A Venture Financing 48
Cormorant Pharma Raises US$2.6 Million In Venture Financing 50
Cardioxyl Pharma Raises US$28 Million In Series B Financing 51
Partnerships 52
Clinigen and Bristol-Myers Squibb Enter into Agreement 52
Bristol-Myers Squibb Expands Collaboration with Flatiron Health 53
Advantagene Enters into Agreement with Bristol-Myers Squibb 54
Lupus Therapeutics Enters into Agreement with Bristol-Myers Squibb 55
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 56
Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 57
Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 58
Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 59
Replimune Enters into Co-Development Agreement with Bristol-Myers Squibb 61
Sirenas Enters into Research Agreement wiith Bristol-Myers Squibb 62
Taris Biomedical and Bristol-Myers Squibb Enter into Partnership 63
Bristol-Myers Squibb Enters into Research Agreement with Kumamoto University 64
AbbVie and Bristol-Myers Squibb Enter into Agreement 65
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 66
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 67
Bristol-Myers Squibb Enters into Partnership with Novartis 68
Bristol-Myers Squibb and Qiagen Enter into Agreement 69
Advaxis and Bristol-Myers Squibb Enter into Agreement 70
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 71
Bristol-Myers Squibb Enters into Research Agreement with Transgene 72
Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 73
Bristol-Myers Squibb Enters into Agreement with Apexigen 74
Bristol-Myers Squibb and Incyte Enter into Agreement 75
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 76
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 77
Exelixis Enters into Agreement with Bristol-Myers Squibb 78
Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 79
Janssen Biotech Enters into Partnership with Bristol-Myers 80
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 81
Target Pharma Extends Agreement with Bristol-Myers Squibb 82
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 83
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 84
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 85
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 86
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 87
AbbVie and Bristol-Myers Squibb Enter into Agreement 88
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 89
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 90
Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 91
Oncodesign Enters into Agreement with Bristol-Myers Squibb 92
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 93
Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 94
IFM Therapeutics to Enter into Research Agreement with University of Michigan 95
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 96
Bristol-Myers Squibb Enters into Research Agreement with UCLA 97
Bristol-Myers Squibb Enters into Research Agreement with Princeton University 98
Bristol-Myers Squibb Enters into Research Agreement with NCCN 99
Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 100
Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 101
Bristol-Myers Squibb Enters into Agreement with uniQure 102
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 103
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 104
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 105
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 106
OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 108
Bristol-Myers Squibb Enters into Agreement with Celgene 109
Bristol-Myers Squibb Forms Joint Venture with Allied Minds 110
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 111
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 113
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 114
Evotec Enters into Agreement with Padlock Therapeutics 115
Evotec Extends Agreement with Padlock Therapeutics 116
Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 117
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 118
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 119
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 120
Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 122
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 123
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 124
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 125
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinsons Disease 126
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 127
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 128
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 129
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 130
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 131
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 132
Licensing Agreements 133
Bristol-Myers Enters into Licensing Agreement with Domain Therapeutics 133
Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 134
Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 135
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 136
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 137
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 138
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 139
Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 140
Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 141
Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 142
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 143
Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 144
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 146
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 147
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 148
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 150
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 151
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 152
Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 153
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 154
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 155
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 156
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 157
Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 158
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 159
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 160
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 162
Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 164
Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 165
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 167
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 169
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 170
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 171
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 172
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 173
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 174
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 175
Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 177
Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 178
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 179
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 180
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 181
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 182
Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 183
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 184
Equity Offering 185
Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 185
uniQure Raises USD38 Million in Private Placement of Shares 187
Debt Offering 188
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 188
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 190
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 192
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 193
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For US$500 Million 194
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For US$500 Million 196
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For US$500 Million 198
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 200
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 202
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 204
Asset Transactions 206
Bristol-Myers Squibb May Sell its Over The Counter Drugs Business for USD1.16 Billion 206
SK Biotek Acquires API Manufacturing Facility from Bristol-Myers Squibb for USD165 Million 207
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 208
Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 209
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 210
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 211
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 212
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 213
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 214
Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For US$750 Million 215
Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 216
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 217
Acquisition 218
Bristol-Myers Squibb Acquires IFM Therapeutics 218
Bristol-Myers Squibb Acquires Cormorant Pharma 219
Bristol-Myers Squibb Acquires Padlock Therapeutic 220
Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 221
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 222
Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 224
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 225
Pfizer May Acquire Bristol-Myers Squibb 226
Bristol-Myers Squibb Acquires iPierian 227
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For US$4.3 Billion 228
Bristol-Myers Rumored To Acquire Biogen Idec 230
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For US$5.3 Billion 231
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For US$2.5 Billion 233
Bristol-Myers Squibb Co - Key Competitors 235
Bristol-Myers Squibb Co - Key Employees 236
Bristol-Myers Squibb Co - Locations And Subsidiaries 238
Head Office 238
Other Locations & Subsidiaries 238
Joint Venture 244
Recent Developments 245
Strategy And Business Planning 245
Nov 01, 2017: Bristol-Myers Squibb, BioLabs Announce Founding Sponsorship in Support of Promising Biotech Companies in New York 245
Financial Announcements 246
Feb 05, 2018: Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results 246
Oct 26, 2017: Bristol-Myers Squibb Reports Third Quarter Financial Results 248
Jul 27, 2017: Bristol-Myers Squibb Reports Second Quarter Financial Results 250
Apr 27, 2017: Bristol-Myers Squibb Reports First Quarter Financial Results 253
Jan 26, 2017: Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results 256
Corporate Communications 259
Mar 01, 2018: Bristol-Myers Squibb Names Jose Baselga, M.D., Ph.D. to Board of Directors 259
Oct 09, 2017: Bristol-Myers Squibb Appoints Saurabh Saha, M.D., Ph.D., as Senior Vice President, Global Head of Translational Medicine 260
Sep 13, 2017: Bristol-Myers Squibb Names Karen Vousden, Ph.D. to Board of Directors 261
Apr 12, 2017: NICEs draft guidance ignores recommendation of Opdivo to treat cancer, Bristol-Myers Squibb says 262
Mar 08, 2017: Bristol-Myers Squibb Appoints Dr. Thomas J. Lynch, Jr., Executive Vice President and Chief Scientific Officer 263
Feb 21, 2017: Bristol-Myers Squibb Appoints Three New Independent Directors 265
Government and Public Interest 266
May 11, 2018: Young Lung Cancer Investigators Awarded $200K to Improve Lung Cancer Outcomes 266
May 10, 2018: New Grants Totaling $2.6 Million Fund Work to Reduce Immunotherapy Side Effects 267
May 02, 2018: 2cureXs CEO Ole Thastrup will join Folkemodet 2018 in Denmark 268
Oct 26, 2017: Study to test combination therapy for breast cancer 269
Sep 08, 2017: Major breakthroughs spell hope for melanoma patients 270
Product News 271
12/12/2017: PsiOxus Therapeutics Receives $15M Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA 271
Oct 12, 2017: 10 SU2C Catalyst Clinical Trials Launched 272
06/14/2017: Bristol-Myers Squibb To Present on BMS-986165 at the Annual European Congress of Rheumatology (EULAR 2017) 274
06/04/2017: Five Prime Therapeutics Presents Initial Clinical Trial Data from Phase 1/2 trial of Cabiralizumab in Pigmented Villonodular Synovitis (PVNS) at 2017 ASCO Annual Meeting 275
06/03/2017: Anti-LAG-3 (BMS-986016) in Combination with Opdivo (nivolumab) Showed Activity in Patients with Melanoma Who Were Relapsed or Refractory to Anti-PD-1/PD-L1 Therapy 276
May 14, 2018: Researchers test flexible cancer research model 278
May 02, 2018: BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace 279
04/20/2017: Five Prime to Present Clinical Data on cabiralizumab at 2017 ASCO Annual Meeting 280
03/13/2017: Expansion Of Phase I/II Trial Evaluating Lirilumab In Combination With Opdivo (Nivolumab) In Patients With Advanced Solid Tumors 281
Product Approvals 282
Nov 28, 2017: CytomX Therapeutics Announces FDA Acceptance of Investigational New Drug Application for CTLA-4 Probody Therapeutic 282
Jan 24, 2017: European Commission Grants Orphan Drug Designation to Cabiralizumab (FPA008) for Pigmented Villonodular Synovitis 283
Clinical Trials 284
Oct 20, 2017: Bristol-Myers Squibb to Present New Data on its liver disease drug candidate BMS-986036 at The Liver Meeting 2017 284
Apr 22, 2017: Bristol-Myers Squibbs BMS-986036 (Pegylated FGF21) Shows Consistent Improvement in Liver Fat, Liver Injury and Fibrosis in Patients with Nonalcoholic Steatohepatitis (NASH) in Phase 2 Trial 285
Apr 10, 2017: Five Prime Therapeutics Announces Completion of Enrollment for the Phase 2 Part of the Ongoing Trial of Cabiralizumab for the Treatment of Pigmented Villonodular Synovitis 286
Apr 03, 2017: Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting 287
Feb 06, 2017: INNATE PHARMA announces top-line results from EffiKIR trial evaluating the efficacy of lirilumab 288
Other Significant Developments 289
May 31, 2017: PeptiDream Announces 5 th Milestone from Macrocyclic Peptide Drug Discovery Alliance with Bristol-Myers Squibb 289
Feb 27, 2017: Bristol-Myers Squibb Expands International Immuno-Oncology Network (II-ON) With Addition of Columbia University Medical Center and Peter MacCallum Cancer Centre 290
Appendix 291
Methodology 291
About GlobalData 291
Contact Us 291
Disclaimer 291

List Of Tables

List of Tables
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Bristol-Myers Squibb Co, Deals By Therapy Area, 2012 to YTD 2018 15
Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 17
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 18
AstraZeneca And BMS Acquires Exenatide From Eli Lilly Japan 29
Enterome Bioscience Raises USD38.5 Million in Series D Financing 31
TARIS Biomedical Raises USD25 Million in Series B Financing 33
Blade Therapeutics Raises Additional USD18.3 Million in Series B Financing 35
Cardior Pharma Raises USD16.3 Million in Series A Financing 37
IFM Therapeutics Raises USD27 Million in Series A Financing Round 39
Blade Therapeutics Raises USD27 Million in Series B Financing 40
IFM Therapeutics Raises Funds in Seed Financing Round 42
Padlock Therapeutics Raises USD23 Million in Extended Series A Financing 43
Flexus Biosciences Raises USD25 Million in Series B Venture Financing 44
iPierian Raises USD1 Million in Venture Financing 45
Padlock Therapeutics Raises Funds through Series A Financing 46
Flexus Biosciences Raises USD13 Million in Series A Venture Financing 47
iPierian Raises US$30 Million In Series A Venture Financing 48
Cormorant Pharma Raises US$2.6 Million In Venture Financing 50
Cardioxyl Pharma Raises US$28 Million In Series B Financing 51
Clinigen and Bristol-Myers Squibb Enter into Agreement 52
Bristol-Myers Squibb Expands Collaboration with Flatiron Health 53
Advantagene Enters into Agreement with Bristol-Myers Squibb 54
Lupus Therapeutics Enters into Agreement with Bristol-Myers Squibb 55
Bristol-Myers Squibb Enters into Partnership with Janssen Pharma 56
Bristol-Myers Squibb and Illumina Enter into Partnership Agreement 57
Bristol-Myers Squibb Enters into Research Agreement with Harvard Stem Cell Institute 58
Bristol-Myers Squibb and Nektar Therapeutics Extend Co-Development and Commercialization Agreement for NKTR-214 59
Replimune Enters into Co-Development Agreement with Bristol-Myers Squibb 61
Sirenas Enters into Research Agreement wiith Bristol-Myers Squibb 62
Taris Biomedical and Bristol-Myers Squibb Enter into Partnership 63
Bristol-Myers Squibb Enters into Research Agreement with Kumamoto University 64
AbbVie and Bristol-Myers Squibb Enter into Agreement 65
Bristol-Myers Squibb and Daiichi Sankyo Enter into Agreement 66
Bristol-Myers Squibb and Clovis Oncology Enter into Agreement 67
Bristol-Myers Squibb Enters into Partnership with Novartis 68
Bristol-Myers Squibb and Qiagen Enter into Agreement 69
Advaxis and Bristol-Myers Squibb Enter into Agreement 70
Array BioPharma and Bristol-Myers Squibb Enter into Research Agreement 71
Bristol-Myers Squibb Enters into Research Agreement with Transgene 72
Bristol-Myers Squibb Enters into Agreement with Nordic Bioscience 73
Bristol-Myers Squibb Enters into Agreement with Apexigen 74
Bristol-Myers Squibb and Incyte Enter into Agreement 75
Bristol-Myers Squibb Enters into Agreement with Foundation Medicine 76
Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb and Cancer Research Institute Enter into Research Partnership 77
Exelixis Enters into Agreement with Bristol-Myers Squibb 78
Bristol-Myers Squibb Enters into Research Agreement with GeneCentric Diagnostics 79
Janssen Biotech Enters into Partnership with Bristol-Myers 80
Bristol-Myers Squibb and Calithera Biosciences Expand Agreement 81
Target Pharma Extends Agreement with Bristol-Myers Squibb 82
Bristol-Myers Squibb Company Enters into Agreement with John Hopkins University 83
Bristol-Myers Squibb Expands Agreement with Infinity Pharma 84
Bristol-Myers Squibb Enters into Co-Development Agreement with Institut Curie 85
Bristol-Myers Squibb Enters into Research Agreement with Janssen Biotech 86
GreenPeptide Enters into Agreement with Bristol-Myers Squibb 87
AbbVie and Bristol-Myers Squibb Enter into Agreement 88
Bristol-Myers Squibb Enters into Agreement with PsiOxus Therapeutics 89
Bristol-Myers Squibb and University of Texas MD Anderson Enter into Research Agreement 90
Bristol-Myers Squibb Enters into Research Agreement with Dana-Farber Cancer Institute 91
Oncodesign Enters into Agreement with Bristol-Myers Squibb 92
Seattle Genetics and Bristol-Myers Squibb Enter into Clinical Trial Agreement 93
Bristol-Myers Squibb Enters into Agreement with Ohio State University Comprehensive Cancer Center 94
IFM Therapeutics to Enter into Research Agreement with University of Michigan 95
Neon Therapeutics Enters into Agreement with Bristol-Myers Squibb 96
Bristol-Myers Squibb Enters into Research Agreement with UCLA 97
Bristol-Myers Squibb Enters into Research Agreement with Princeton University 98
Bristol-Myers Squibb Enters into Research Agreement with NCCN 99
Bristol-Myers Squibb Enters into Research Agreement with Sidney Kimmel Comprehensive Cancer Center 100
Bristol-Myers Squibb Enters into Research Agreement with Medical University of South Carolina 101
Bristol-Myers Squibb Enters into Agreement with uniQure 102
Rigel Enters into R&D Agreement with Bristol-Myers Squibb for TGF Beta Receptor Kinase Inhibitors 103
Bristol-Myers Squibb Enters into Agreement with Eli Lilly 104
Bristol-Myers Squibb and Seattle Genetics Enter into Agreement 105
Bristol-Myers Squibb Enters into Agreement with Five Prime Therapeutics for Opdivo and FPA008 106
OliPass Enters into Co-Development Agreement with Bristol-Myers Squibb 108
Bristol-Myers Squibb Enters into Agreement with Celgene 109
Bristol-Myers Squibb Forms Joint Venture with Allied Minds 110
Bristol-Myers Squibb Enters into Co-Development Agreement with Ono Pharma 111
Syngene International Extends R&D Agreement with Bristol-Myers Squibb 113
Pierre Fabre Enters into Co-Promotion Agreement with Bristol-Myers Squibb for Orencia 114
Evotec Enters into Agreement with Padlock Therapeutics 115
Evotec Extends Agreement with Padlock Therapeutics 116
Immuneering Enters Into Agreement With Bristol-Myers Squibb For New Medicines 117
AstraZeneca Enters Into Agreement With Bristol-Myers To Commercialize Dapagliflozin In Japan 118
Bristol-Myers Squibb And Samsung BioLogics Enter Into Agreement For Antibody Cancer Drug 119
Bristol-Myers Squibb Expands Co-Development Agreement With Simcere Pharma For Orencia 120
Ambrx Enters Into Co-Development Agreement With Bristol-Myers Squibb 122
Santaris Pharma Enters Into Agreement With Bristol-Myers Squibb For RNA-Targeted Medicines 123
Merck Serono Enters Into Co-Promotion Agreement With Bristol-Myers Squibb For Glucophage 124
Valeant Pharma Enters into Option Agreement with Bristol-Myers Squibb 125
Vanderbilt University Enters Into Agreement With Bristol-Myers Squibb To Develop Drugs For Parkinsons Disease 126
Prosetta Enters Into Co-Development Agreement With Bristol-Myers Squibb For Antiviral Drugs 127
Bristol-Myers Squibb Enters Into Co-Development Agreement With Emory University 128
Scripps Research Institute Enters Into Research Agreement With Bristol-Myers Squibb 129
Bristol-Myers Squibb Enters Into Co-Development Agreement With Tsinghua University 130
Bristol-Myers Squibb Enters Into Co-Development Agreement With Duke Translational Medicine Institute 131
Ensemble Therapeutics Extends Co-Development Agreement With Bristol-Myers Squibb 132
Bristol-Myers Enters into Licensing Agreement with Domain Therapeutics 133
Bristol-Myers Squibb Enters into Licensing Agreement with Ono Pharma for ONO-4578 134
Ayala Pharma Enters into Licensing Agreement with Bristol-Myers Squibb 135
Bristol-Myers Squibb and Halozyme Therapeutics Enter into License Agreement 136
Biogen Enters into Licensing Agreement with Bristol-Myers Squibb 137
Roche to Enter into Licensing Agreement with Bristol-Myers Squibb 138
Merck Enters into Licensing Agreement with Bristol-Myers Squibb and Ono Pharma 139
Bristol-Myers Squibb Enters into Licensing Agreement with PsiOxus Therapeutics 140
Bristol-Myers Squibb Enters into Licensing Agreement with Enterome 141
Bristol-Myers Squibb Enters into Licensing Agreement with Nitto Denko 142
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company for Daclatasvir 143
Biohaven Pharma Amends Licensing Agreement with Bristol-Myers Squibb 144
Mylan Enters into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 146
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 147
Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 148
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 150
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 151
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 152
Padlock Therapeutics Enters into Licensing Agreement with GlaxoSmithKline 153
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 154
Zai Lab Enters Into Licensing Agreement With Bristol-Myers Squibb 155
Bristol-Myers Squibb Enters into Option for Licensing Agreement with Bavarian Nordic 156
Bristol-Myers Squibb Enters into Licensing Agreement with California Institute for Biomedical Research 157
Padlock Therapeutics Enters into Licensing Agreement with Scripps Research Institute 158
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 159
Bristol-Myers Squibb Extends Licensing Agreement with CytomX Therapeutics 160
Five Prime Therapeutics Expands Licensing Agreement with Bristol-Myers Squibb 162
Medicines Patent Pool Extends Licensing Agreement With Bristol-Myers Squibb 164
Reckitt Benckiser Amends Licensing Agreement With Bristol-Myers Squibb For OTC Brands 165
Medicines Company Enters Into Licensing Agreement With Bristol-Myers Squibb For Recothrom 167
Biocon Enters Into Option For Licensing Agreement With Bristol-Myers Squibb 169
Sanofi Enters into Licensing Agreement with Bristol-Myers Squibb 170
University Of Montreal Enters Into Licensing Agreement With Bristol-Myers Squibb 171
Summit Enters Into Licensing Agreement With Bristol-Myers Squibb For Seglin Technology 172
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 173
MPP, Bristol-Myers Squibb and Laurus Labs Enter into Licensing Agreement For Daclatasvir 174
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 175
Medicines Patent Pool Enters into Licensing Agreement with Bristol-Myers Squibb For Daclatasvir 177
Bristol-Myers Squibb Enters into Licensing Agreement with QIMR Berghofer Medical Research Institute 178
Bristol-Myers Squibb Enters into Licensing Agreement with R-Pharm 179
Bristol-Myers Squibb Enters Into Licensing Agreement With Kyowa Hakko Kirin For Coniel In China 180
PeptiDream Expands Agreement With Bristol-Myers Squibb For Drug Discovery 181
PeptiDream Enters Into Licensing Agreement With Bristol-Myers Squibb For Peptide Discovery Platform System 182
Chiromics Enters Into Licensing Agreement With Bristol-Myers Squibb For Chemical Compounds 183
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 184
Nektar Therapeutics Raises USD850 Million in Private Placement of Shares 185
uniQure Raises USD38 Million in Private Placement of Shares 187
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 1.6% Notes Due 2019 188
Bristol-Myers Squibb Raises USD750 Million in Public Offering of 3.25% Notes Due 2027 190
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1% Notes Due 2025 192
Bristol-Myers Squibb Raises USD628 Million in Public Offering of 1.75% Notes Due 2035 193
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2019 For US$500 Million 194
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2023 For US$500 Million 196
Bristol-Myers Squibb Completes Public Offering Of Notes Due 2044 For US$500 Million 198
Bristol-Myers Squibb Completes Public Offering Of 3.25% Senior Unsecured Notes Due 2042 For US$500 Million 200
Bristol-Myers Squibb Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$750 Million 202
Bristol-Myers Squibb Completes Public Offering Of 2% Senior Unsecured Notes Due 2022 For US$750 Million 204
Bristol-Myers Squibb May Sell its Over The Counter Drugs Business for USD1.16 Billion 206
SK Biotek Acquires API Manufacturing Facility from Bristol-Myers Squibb for USD165 Million 207
Seattle Genetics to Acquire Pharma Manufacturing Facility from Bristol-Myers Squibb 208
Reckitt Benckiser Exercises Option to Acquire OTC Products of Bristol-Myers Squibb for USD317 Million 209
ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 210
ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 211
R-Pharm US Acquires Rights to IXEMPRA from Bristol-Myers Squibb 212
Medicines Company Exercises Option to Acquire Recothrom from Bristol-Myers Squibb for USD132 Million 213
PharmaSwiss Acquires Trademarks and Intellectual Property of Certain Products from Bristol-Myers Squibb for USD61 Million 214
Bristol-Myers Squibb Reportedly To Sell Plavix And Avapro For US$750 Million 215
Emcure Pharma Acquires Rights of BiCNU Injection from Bristol-Myers Squibb 216
Synergy Pharma Acquires FV-100 From Bristol-Myers Squibb 217
Bristol-Myers Squibb Acquires IFM Therapeutics 218
Bristol-Myers Squibb Acquires Cormorant Pharma 219
Bristol-Myers Squibb Acquires Padlock Therapeutic 220
Bristol-Myers Squibb Acquires Cardioxyl Pharma for up to USD2.1 Billion 221
Bristol-Myers Squibb Enters into Option to Acquire Promedior and PRM-151 for up to USD1.25 Billion 222
Bristol-Myers Squibb Acquires Flexus Biosciences for up to USD1.25 Billion 224
Bristol-Myers Squibb Enters into Option to Acquire Galecto Biotech and TD-139 225
Pfizer May Acquire Bristol-Myers Squibb 226
Bristol-Myers Squibb Acquires iPierian 227
AstraZeneca Completes Acquisition Of Remaining 50% Interest In Diabetes Joint Venture From Bristol-Myers Squibb For US$4.3 Billion 228
Bristol-Myers Rumored To Acquire Biogen Idec 230
Bristol-Myers Squibb Completes Acquisition Of Amylin Pharma For US$5.3 Billion 231
Bristol-Myers Squibb Completes Acquisition Of Inhibitex, Hepatitis C Drug Developer, For US$2.5 Billion 233
Bristol-Myers Squibb Co, Key Competitors 235
Bristol-Myers Squibb Co, Key Employees 236
Bristol-Myers Squibb Co, Subsidiaries 238
Bristol-Myers Squibb Co, Joint Venture 244

List Of Figures

List of Figures
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 12
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 13
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 14
Bristol-Myers Squibb Co, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 15
Bristol-Myers Squibb Co, Medical Devices Deals, 2012 to YTD 2018 17

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available